Faculty, Staff and Student Publications
Publication Date
8-1-2022
Journal
Lancet Oncology
Abstract
The Gynecologic Cancer InterGroup (GCIG) sixth Ovarian Cancer Conference on Clinical Research was held virtually in October, 2021, following published consensus guidelines. The goal of the consensus meeting was to achieve harmonisation on the design elements of upcoming trials in ovarian cancer, to select important questions for future study, and to identify unmet needs. All 33 GCIG member groups participated in the development, refinement, and adoption of 20 statements within four topic groups on clinical research in ovarian cancer including first line treatment, recurrent disease, disease subgroups, and future trials. Unanimous consensus was obtained for 14 of 20 statements, with greater than 90% concordance in the remaining six statements. The high acceptance rate following active deliberation among the GCIG groups confirmed that a consensus process could be applied in a virtual setting. Together with detailed categorisation of unmet needs, these consensus statements will promote the harmonisation of international clinical research in ovarian cancer.
Keywords
Carcinoma, Ovarian Epithelial, Consensus, Female, Forecasting, Humans, Ovarian Neoplasms
DOI
10.1016/S1470-2045(22)00139-5
PMID
35901833
PMCID
PMC9465953
PubMedCentral® Posted Date
8-1-2023
PubMedCentral® Full Text Version
Author MSS
Correction
Published Open-Access
yes
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Genetic Phenomena Commons, Medical Genetics Commons, Oncology Commons
Comments
This article has been corrected. See Lancet Oncol. 2022 Sep;23(9):e404. See commentary "Appropriateness of integrating survival with quality of life and toxicity measures in a single endpoint in ovarian cancer clinical trials." on page e480.